Opus Genetics (IRD) Cash from Investing Activities (QoQ) (2010 - 2019)
Powered by 
Analysis
Opus Genetics (IRD) Cash from Investing Activities (QoQ) (2010 - 2019) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | -104.12% |
| Sep 30, 2019 | 0.21% |
| Jun 30, 2019 | 150.78% |
| Mar 31, 2019 | -394.76% |
| Dec 31, 2018 | -45.42% |
| Sep 30, 2018 | 12.79% |
| Jun 30, 2018 | 8.39% |
| Mar 31, 2018 | 197.87% |
| Dec 31, 2017 | -202.21% |
| Sep 30, 2017 | 129.91% |
| Jun 30, 2017 | -1,510.17% |
| Mar 31, 2017 | -84.82% |
| Dec 31, 2016 | 345.47% |
| Sep 30, 2016 | -176.96% |
| Jun 30, 2016 | 423.23% |
| Mar 31, 2016 | 82.08% |
| Dec 31, 2015 | -161.46% |
| Sep 30, 2015 | 164.08% |
| Jun 30, 2015 | -37.79% |
| Mar 31, 2015 | 289.66% |